Overview An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Status: Completed Trial end date: 2018-03-01 Target enrollment: Participant gender: Summary The purpose of this study is to investigate the superiority of KPS-0373 to placebo, and evaluate the safety of KPS-0373 in SCD patients. Phase: Phase 3 Details Lead Sponsor: Kissei Pharmaceutical Co., Ltd.